Biktarvy is a single daily pill that combines three antiviral drugs to block HIV at two different stages of its life cycle. By attacking the virus from multiple angles simultaneously, it suppresses HIV to undetectable levels in about 95–97% of people within 48 weeks. Here’s what’s happening inside your body when you take it.
Three Drugs in One Pill
Biktarvy contains three active ingredients, each with a distinct job. Bictegravir is an integrase inhibitor, meaning it targets a specific HIV enzyme. Emtricitabine and tenofovir alafenamide (TAF) are both reverse transcriptase inhibitors, meaning they interfere with a different HIV enzyme earlier in the virus’s replication process. Combining all three into one tablet simplifies treatment to a single pill taken once a day, with or without food.
How HIV Normally Copies Itself
To understand what Biktarvy blocks, it helps to know how HIV hijacks your cells. After HIV enters a type of immune cell called a CD4 cell, it needs to convert its genetic material (RNA) into DNA. An enzyme called reverse transcriptase handles that conversion. Once the virus has created a DNA copy of itself, a second enzyme called integrase splices that viral DNA into your cell’s own DNA. At that point, your cell’s normal machinery starts producing new copies of the virus, which burst out and infect more cells.
Biktarvy interrupts both of those steps.
Blocking Reverse Transcriptase
Emtricitabine and tenofovir alafenamide work at the first critical step. Both drugs mimic the building blocks that reverse transcriptase uses to assemble viral DNA. When the enzyme grabs one of these decoy molecules instead of a real building block, the growing DNA chain can’t continue. The result: HIV fails to produce a usable DNA copy of its genome, and replication stalls before it truly begins.
Having two drugs targeting the same enzyme matters because it makes it much harder for the virus to develop workarounds. A single mutation might let HIV dodge one drug, but evading two at the same time is far less likely.
Blocking Integration
Bictegravir handles the second step. Even if some viral DNA slips past the first line of defense, bictegravir prevents it from being stitched into your cell’s DNA. It does this by binding to the integrase enzyme at the exact moment the enzyme is trying to connect viral DNA to your chromosomes. Specifically, bictegravir latches onto metal ions and the viral DNA within the enzyme’s active site, physically displacing the viral DNA and deactivating the whole complex. Without successful integration, the virus can’t commandeer your cell to produce more copies of itself.
This class of drugs, called integrase strand transfer inhibitors, has become a cornerstone of modern HIV treatment because of its potency and tolerability. Bictegravir has an especially high barrier to resistance: treatment-emergent resistance mutations appear in fewer than 1% of people starting therapy for the first time.
How Effective It Is
In real-world studies pooling data from thousands of patients, 97% of people starting HIV treatment for the first time reached an undetectable viral load (below 50 copies per milliliter of blood) within 48 weeks. Among people switching to Biktarvy from a different regimen, that figure was 95%, with suppression above 93% across every individual study analyzed. An undetectable viral load means the amount of virus in your blood is so low that standard tests can’t measure it, and at that level HIV cannot be transmitted sexually.
Why TAF Instead of Older Tenofovir
Tenofovir has been a backbone of HIV treatment for over two decades, but earlier versions of the drug (tenofovir disoproxil fumarate, or TDF) could gradually affect kidney function and bone density. Biktarvy uses a newer formulation, tenofovir alafenamide, which delivers the active drug more efficiently to cells. That means a much smaller dose reaches the bloodstream and kidneys.
In phase 3 trials comparing the two formulations head to head, people taking TAF-based regimens had significantly less protein in their urine (a marker of kidney stress), smaller increases in a key kidney function marker called serum creatinine, and roughly half the bone density loss at the spine and hip after 48 weeks. For people who will take antiretroviral therapy for decades, these differences in long-term organ health add up.
Common Side Effects
Biktarvy is generally well tolerated. In clinical trials of people starting treatment for the first time, the most commonly reported side effects at 48 weeks were diarrhea (3–6%), nausea (3–5%), and headache (4–5%). Fatigue, abnormal dreams, dizziness, and insomnia each occurred in about 1–3% of participants. Notably, no moderate or severe side effects occurred in more than 1% of people taking the drug, and nausea rates were substantially lower than with some competing regimens.
Most of these side effects tend to be mild and often ease within the first few weeks as your body adjusts.
Dosing for Adults and Children
For adults and children weighing 25 kg (about 55 pounds) or more, the standard dose is one tablet once daily. A lower-strength tablet is available for children weighing between 14 and 25 kg. There is currently no approved dose for children under 2 years old or weighing less than 14 kg. The pill can be taken with or without food, which makes it straightforward to fit into any daily routine.
Resistance and Long-Term Reliability
One of Biktarvy’s strongest selling points is its high genetic barrier to resistance. HIV mutates constantly, and with some older drugs, a single mutation could allow the virus to escape treatment. Bictegravir requires multiple simultaneous mutations to lose effectiveness, which is extremely unlikely when the drug is taken consistently. In clinical data, resistance to bictegravir emerged in fewer than 1% of treatment-naive patients. Combining it with two additional drugs from a different class makes the overall regimen even more durable, because the virus would need to simultaneously overcome three separate obstacles to replicate freely.
This is why consistency matters. Taking the pill at roughly the same time each day keeps drug levels steady in your body, giving HIV no window to replicate and accumulate mutations.